Essex Bio-Technology (HKG:1061) expects profit for the first half of 2026 to decline by approximately 30% from HK$163.4 million a year earlier, according to a Friday Hong Kong bourse filing.
Revenue for the period is expected to decrease by approximately 10% from HK$876.5 million in the corresponding period of 2025.
The company attributed the expected decline mainly to higher VAT expenses following the implementation of China's new VAT law.